To the full analysis
Ascendis Pharma stock: balance sheet and debt
ASNDAscendis Pharma has a debt to equity ratio of −5.35.
Daily figure as of 13 Nov 2026
Debt / Equity
−5.35
Interest coverage
−1.6x
Current ratio
1.04
Cash & equivalents
$682.34M
Total assets
$1.44B
Equity ratio
−12.5%
Goodwill
$3.87M
Plus intangible assets of $238.14K
Net debt
$283.27M
Total assets and equity ratio
How large the balance sheet of Ascendis Pharma A/S is, how much of it is equity and how much is goodwill from acquisitions.
Equity ratio
Figures as a table
| Year | Total assets | Goodwill and intangible assets | of which goodwill | Equity ratio | Net debt |
|---|---|---|---|---|---|
| 2012 | $28.15M | $3.87M | $3.87M | 6.1% | −$15.87M |
| 2013 | $29.59M | $3.87M | $3.87M | 23.6% | −$21.53M |
| 2014 | $65.01M | $3.87M | $3.87M | 78.1% | −$55.59M |
| 2015 | $146.02M | $3.87M | $3.87M | 91.3% | −$132.58M |
| 2016 | $210.62M | $3.87M | $3.87M | 92.9% | −$199.82M |
| 2017 | $233.79M | $3.87M | $3.87M | 88.7% | −$216.47M |
| 2018 | $353.45M | $3.87M | $3.87M | 87.8% | −$307.9M |
| 2019 | $749.89M | $3.87M | $3.87M | 88.2% | −$622.18M |
| 2020 | $1.09B | $6.34M | $3.87M | 85.6% | −$694.58M |
| 2021 | $1.2B | $5.84M | $3.87M | 81.4% | −$523.18M |
| 2022 | $1.21B | $5.35M | $3.87M | 24.2% | −$130.63M |
| 2023 | $914.83M | $4.9M | $3.87M | −17.6% | $380.76M |
| 2024 | $1.31B | $4.46M | $3.87M | −9.0% | $329.19M |
| 2025 | $1.44B | $4.11M | $3.87M | −12.5% | $283.27M |
The equity ratio divides total equity, including non-controlling interests, by total assets. Net debt is debt minus cash and short-term investments; a negative figure means cash exceeds debt.
Equity and debt
What the company owns and owes
- Cash & equivalents
- Equity
- Debt
Figures as a table
| Year | Cash & equivalents | Equity | Debt | Debt / Equity |
|---|---|---|---|---|
| 2012 | $16.11M | $1.72M | $234.92K | 0.14 |
| 2013 | $21.53M | $6.98M | $0 | 0 |
| 2014 | $55.59M | $50.76M | $0 | 0 |
| 2015 | $132.58M | $133.34M | $0 | 0 |
| 2016 | $199.82M | $195.7M | $0 | 0 |
| 2017 | $216.47M | $207.45M | $0 | 0 |
| 2018 | $307.9M | $310.32M | $0 | 0 |
| 2019 | $662.76M | $661.66M | $40.58M | 0.06 |
| 2020 | $796.5M | $929.38M | $101.92M | 0.11 |
| 2021 | $755.8M | $979.16M | $232.61M | 0.24 |
| 2022 | $814.96M | $291.82M | $684.33M | 2.35 |
| 2023 | $442.62M | −$161.45M | $823.38M | −5.1 |
| 2024 | $620.03M | −$117.13M | $949.22M | −8.1 |
| 2025 | $682.34M | −$180.35M | $965.61M | −5.35 |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 7 Aug 2026)
- Valuation signal Fairly valued since 7 Nov 2026, previously Undervalued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.